Ipilimumab and whole brain radiation therapy for melanoma brain metastases

Journal of Neuro-Oncology

Volumn 121, Issue 1, 2015, Pages 159-165

  Gerber, Naamit K ^a   Young, Robert J ^a   Barker, Christopher A ^a   Wolchok, Jedd D ^a,b   Chan, Timothy A ^a   Yamada, Yoshiya ^a   Friguglietti, Leigh ^a   Beal, Kathryn ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Brain metastases; Immunotherapy; Ipilimumab; Melanoma; Whole brain radiotherapy

Indexed keywords

IPILIMUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN METASTASIS; BRAIN RADIATION; CLINICAL ARTICLE; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; DIPLOPIA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HEADACHE; HUMAN; INTRATUMORAL HEMORRHAGE; MALE; MELANOMA; MELANOMA METASTASIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SEIZURE; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION; ADVERSE EFFECTS; BRAIN; BRAIN NEOPLASMS; DRUG EFFECTS; FOLLOW UP; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RADIATION RESPONSE; SECONDARY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BRAIN; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MELANOMA; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84921938937     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-014-1617-9     Document Type: Article

References (34)

1. Bafaloukos D, Gogas H (2004) The treatment of brain metastases in melanoma patients. Cancer Treat Rev 30:515–520
2. Fife KM, Colman MH, Stevens GN, Firth IC, Moon D, Shannon KF, Harman R, Petersen-Schaefer K, Zacest AC, Besser M, Milton GW, McCarthy WH, Thompson JF (2004) Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 22:1293–1300
3. Staudt M, Lasithiotakis K, Leiter U, Meier F, Eigentler T, Bamberg M, Tatagiba M, Brossart P, Garbe C (2010) Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer 102:1213–1218
4. Sampson JH, Carter JH Jr, Friedman AH, Seigler HF (1998) Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 88:11–20
5. Mornex F, Thomas L, Mohr P, Hauschild A, Delaunay MM, Lesimple T, Tilgen W, Bui BN, Guillot B, Ulrich J, Bourdin S, Mousseau M, Cupissol D, Bonneterre ME, De Gislain C, Bensadoun RJ, Clavel M (2003) A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res 13:97–103
6. Douglas JG, Margolin K (2002) The treatment of brain metastases from malignant melanoma. Semin Oncol 29:518–524
7. Ellerhorst J, Strom E, Nardone E, McCutcheon I (2001) Whole brain irradiation for patients with metastatic melanoma: a review of 87 cases. Int J Radiat Oncol Biol Phys 49:93–97
8. Hauswald H, Dittmar JO, Habermehl D, Rieken S, Sterzing F, Debus J, Combs SE (2012) Efficacy and toxicity of whole brain radiotherapy in patients with multiple cerebral metastases from malignant melanoma. Radiat Oncol 7:130
9. Raizer JJ, Hwu WJ, Panageas KS, Wilton A, Baldwin DE, Bailey E, von Althann C, Lamb LA, Alvarado G, Bilsky MH, Gutin PH (2008) Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro-Oncology 10:199–207
10. Meyners T, Heisterkamp C, Kueter JD, Veninga T, Stalpers LJ, Schild SE, Rades D (2010) Prognostic factors for outcomes after whole-brain irradiation of brain metastases from relatively radioresistant tumors: a retrospective analysis. BMC Cancer 10:582
11. Rades D, Heisterkamp C, Huttenlocher S, Bohlen G, Dunst J, Haatanen T, Schild SE (2010) Dose escalation of whole-brain radiotherapy for brain metastases from melanoma. Int J Radiat Oncol Biol Phys 77:537–541
12. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, Werner-Wasik M, Demas W, Ryu J, Bahary JP, Souhami L, Rotman M, Mehta MP, Curran WJ Jr (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363:1665–1672
13. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, Markesbery WR, Macdonald JS, Young B (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322:494–500
14. Soffietti R, Trevisan E, Ruda R (2012) Targeted therapy in brain metastasis. Curr Opin Oncol 24:679–686
15. Robert C, Thomas L, Bondarenko I, O’Day S, DJ M, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517–2526
16. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723
17. Prins RM, Vo DD, Khan-Farooqi H, Yang MY, Soto H, Economou JS, Liau LM, Ribas A (2006) NK and CD4 cells collaborate to protect against melanoma tumor formation in the brain. J Immunol 177:8448–8455
18. Wilson EH, Weninger W, Hunter CA (2010) Trafficking of immune cells in the central nervous system. J Clin Investig 120:1368–1379
19. Grossman SA, Ye X, Lesser G, Sloan A, Carraway H, Desideri S, Piantadosi S (2011) Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res 17:5473–5480
20. Barker C, Postow M (2014) Combinations of radiotherapy and immunotherapy for melanoma: a review of clinical outcomes. Int J Radiat Oncol Biol Phys 88:986–987
21. Weber JS, Amin A, Minor D, Siegel J, Berman D, O’Day SJ (2011) Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. Melanoma Res 21:530–534
22. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, Richards J, Michener T, Balogh A, Heller KN, Hodi FS (2012) Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13:459–465
23. Knisely JP, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VL (2012) Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg 117:227–233
24. Kiess A, Wolchok J, Barker C et al (2012) Ipilimumab and stereotactic radiosurgery for melanoma brain metastases. Int J Radiat Oncol Biol Phys 84:S115–S116
25. Mathew M, Tam M, Ott PA, Pavlick AC, Rush SC, Donahue BR, Golfinos JG, Parker EC, Huang PP, Narayana A (2013) Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res 23:191–195
26. Muller-Brenne T, Rudolph B, Schmidberger H et al (2011) Successful therapy of a cerebral metastasized malign melanoma by whole-brain-radiation and therapy with ipilimumab. J Dtsch Dermatol Ges 9:787–788
27. Bot I, Blank CU, Brandsma D (2012) Clinical and radiological response of leptomeningeal melanoma after whole brain radiotherapy and ipilimumab. J Neurol 259:1976–1978
28. Weber JS, O’Day S, Urba W, Powderly J, Nichol G, Yellin M, Snively J, Hersh E (2008) Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 26:5950–5956
29. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Sneed PK, Chao ST, Weil RJ, Suh J, Bhatt A, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisely JP, Sperduto CM, Lin N, Mehta M (2012) Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30:419–425
30. Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412–7420
31. Isiklar I, Leeds NE, Fuller GN, Kumar AJ (1995) Intracranial metastatic melanoma: correlation between MR imaging characteristics and melanin content. Am J Roentgenol 165:1503–1512
32. Premkumar A, Marincola F, Taubenberger J, Chow C, Venzon D, Schwartzentruber D (1996) Metastatic melanoma: correlation of MRI characteristics and histopathology. J Magn Reson Imaging 6:190–194
33. Hatzoglou V, Ulaner GA, Zhang Z, Beal K, Holodny AI, Young RJ (2013) Comparison of the effectiveness of MRI perfusion and fluorine-18 FDG PET-CT for differentiating radiation injury from viable brain tumor: a preliminary retrospective analysis with pathologic correlation in all patients. Clin Imaging 37:451–457
34. Byrne TN, Cascino TL, Posner JB (1983) Brain metastasis from melanoma. J Neurooncol 1:313–317